Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Insmed Incorporated Shares Skyrocketed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Insmed (NASDAQ: INSM  ) , a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious lung diseases, surged as much as 41% this morning after announcing that the Food and Drug Administration had granted its lead investigational drug Arikayce the highly coveted breakthrough therapy designation.

So what: According to Insmed's 8-K filing with the Securities and Exchange Commission prior to market open, the FDA granted Arikayce the breakthrough therapy designation for the treatment of adults with nontuberculous mycobacterial lung diseases that are treatment refractory. The FDA based its designation on Insmed's phase 2 study results, and now Insmed will work with the FDA to determine the optimal pathway to a possible regulatory approval for Arikayce. As a refresher, the breakthrough therapy designation allows investigational drugs with game-changing potential to potentially file new drug applications using early and mid-stage data as the basis for approval. It can also result in an expedited review process once an NDA is filed.

Now what: The breakthrough designation on Insmed comes as a bit of a surprise given how mixed its phase 2 results were for Arikayce. While the secondary endpoint of culture conversion heavily favored the Arikayce-treated group with considerably more culture negative patients than the placebo at days 84 and 168, which is a positive, Arikayce also failed to meet its primary endpoint of a statistically significant change in mycobacterial density using a seven-point scale from baseline through week 12. Not to mention that Arikayce was also associated with a higher number of adverse events during its phase 2 study relative to the control arm. Though today's move is clearly positive in that it could push Arikayce toward a new drug application very soon, I'm not sold on Insmed or its lead drug as of yet and would suggest sticking to the sidelines following today's romp higher.

Insmed may be skyrocketing today, but keeping up with this top stock over the long run might prove impossible! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2999258, ~/Articles/ArticleHandler.aspx, 9/4/2015 9:30:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 14 minutes ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 3:59 PM
INSM $24.05 Down -0.26 -1.07%
INSMED, INC. CAPS Rating: ***